文献速递外周动脉疾病

腔内时代股腘旁路术治疗慢性肢体威胁性缺血的长期结局评估

Evaluation of Long-Term Outcomes of Femoropopliteal Bypass Surgery in Patients With Chronic Limb-Threatening Ischemia in an Endovascular Era.
PubMed 文献 · Ann Vasc Surg · 2021-10-10

该回顾性研究分析了2007年至2019年间432例股腘旁路术患者,其中CLTI患者200例(46.3%)。5年随访显示CLTI与间歇性跛行患者的一期通畅率分别为58.1%和58.3%,二期通畅率分别为74.1%和68.6%,免于MALE分别为64.5%和61.9%。在CLTI组中,自体静脉移植物5年二期通畅率(83.2%)和免于MALE(72.0%)优于PTFE和HePTFE。

要点

  • 股腘旁路术治疗TASC D病变长期安全有效,CLTI与跛行患者5年通畅率相近。
  • CLTI患者中自体静脉移植物5年二期通畅率和免于MALE优于人工血管。
  • 膝上位置人工血管可作为大隐静脉不可用时的可接受替代方案。

核心结论

  • 股腘旁路术治疗TASC D病变在长期随访中安全有效。
  • 自体静脉移植物仍是CLTI患者膝上旁路术的首选。
  • 膝上位置人工血管在大隐静脉不可用时是可接受的替代选择。

研究设计与样本

  • 回顾性分析2007年1月至2019年3月单中心连续股腘旁路术患者。
  • 共纳入432例股腘移植物,其中跛行232例(53.7%),CLTI 200例(46.3%)。
  • 移植物材料为自体静脉186例(43.1%)、PTFE 128例(29.6%)、HePTFE 118例(27.3%)。

主要发现

  • CLTI与跛行患者5年一期通畅率分别为58.1%和58.3%。
  • CLTI与跛行患者5年二期通畅率分别为74.1%和68.6%。
  • CLTI与跛行患者5年免于MALE分别为64.5%和61.9%。
  • CLTI组5年自体静脉一期通畅率为63.2%(P=0.324)。
  • CLTI组5年自体静脉二期通畅率为83.2%(P=0.020),免于MALE为72.0%,PTFE为47.9%,HePTFE为52.9%(P=0.021)。

临床怎么用

  • 对CLTI合并TASC D股腘病变患者,可考虑股腘旁路术作为长期血运重建策略。
  • 膝上旁路优先选用自体静脉以改善二期通畅率和减少MALE。
  • 大隐静脉不可用时,膝上位置可选用PTFE或HePTFE人工血管。

局限性

  • 回顾性单中心设计可能引入选择偏倚。
  • 原文未报告具体混杂因素控制方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the long-term outcomes of femoropopliteal bypass surgery in patients with chronic limb-threatening ischemia (CLTI) and TransAtlantic Inter-Society Consensus II (TASC II), type D (TASC D) femoropopliteal disease. METHODS: A retrospective analysis was performed for all consecutive patients undergoing above-knee (AK) femoropopliteal bypass surgery at an academic vascular centre between January 2007 and March 2019. Patients with claudication (IC) and patients with CLTI were included. Patency rates and freedom from major adverse limb events (MALE) after 5 years were analysed. RESULTS: In total, 432 femoropopliteal grafts were performed. Indications for surgery were claudication and CLTI in 232 (53.7%) and 200 (46.3%) patients, respectively. Graft material was autologous vein in 186 patients (43.1%), polytetrafluoroethylene (PTFE) in 128 patients (29.6%), and heparin-bonded expanded polytetrafluoroethylene (HePTFE) in 118 patients (27.3%). At the 5-year follow-up, the primary patency rate was 58.1% and 58.3% in patients with CLTI and claudication, respectively. Secondary patency rates were 74.1% and 68.6%, respectively. Freedom from MALE was 64.5% and 61.9%, respectively. Analyses of graft material in the CLTI group showed that, at 5 years, autologous vein grafts had better long-term patency rates than PTFE and HePTFE grafts. At 5 years, the primary and secondary patency rate for autologous vein grafts were 63.2% (P= 0.324) and 83.2% (P = 0.020), respectively. Freedom from MALE was 72.0% with the use of autologous vein grafts, 47.9% using PTFE and, 52.9% using HePTFE, respectively (P= 0.021). CONCLUSIONS: Our study shows that femoropopliteal bypass surgery in patients with TASC D lesions is safe and effective in the long term. Autologous vein grafts remain the first choice for patients with CLTI, also for bypasses in AK position. However, prosthetic grafts in AK the position are an acceptable alternative for revascularisation when the saphenous vein is not available.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Betz T, Ingolf T, Markus S, et al. Evaluation of Long-Term Outcomes of Femoropopliteal Bypass Surgery in Patients With Chronic Limb-Threatening Ischemia in an Endovascular Era. Ann Vasc Surg. 2021. PMID: 34644653. doi:10.1016/j.avsg.2021.06.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。